SCHEDULE 13G/A: Major Investor Orin Hirschman and AIGH Capital Management Disclose 5.1% Stake in Grace Therapeutics

Orin Hirschman and AIGH Capital Management LLC have jointly disclosed a 5.1% beneficial ownership stake in Grace Therapeutics, Inc.'s Common Stock as of December 31, 2024.

Summary

• Orin Hirschman and AIGH Capital Management LLC, along with AIGH Investment Partners, L.L.C., are the reporting persons for this Schedule 13G filing.
• The filing discloses beneficial ownership of 521,083 shares of Grace Therapeutics, Inc. Common Stock.
• This aggregate amount represents 5.1% of the total class of securities.
• The reporting persons hold sole voting power and sole dispositive power over all 521,083 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Grace Therapeutics, Inc.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would typically indicate positive or negative sentiment regarding company performance or outlook. The presence of a significant investor could be seen as a neutral to slightly positive signal.

Positives

• The disclosure of a significant beneficial ownership stake (5.1%) by an investment firm and its managing member may be viewed by the market as a sign of investor confidence in Grace Therapeutics, Inc.

Future Outlook

This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a standard regulatory disclosure of a significant ownership stake by an institutional investor in a publicly traded company. It reflects an investment decision by AIGH Capital Management and Orin Hirschman in Grace Therapeutics, Inc., rather than broader industry trends.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment firm may be viewed positively as a sign of investor confidence in Grace Therapeutics, Inc.

Key Dates

Keywords

Grace Therapeutics, Orin Hirschman, AIGH Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Stake